# Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

> **NCT05639933** · PHASE2 · RECRUITING · sponsor: **Hoth Therapeutics, Inc.** · enrollment: 152 (estimated)

## Conditions studied

- Acneiform Eruption Due to Chemical
- Xerosis Cutis
- Paronychia

## Interventions

- **DRUG:** HT-001 2% Topical Gel
- **DRUG:** HT-001 1% Topical Gel
- **DRUG:** HT-001 0.5% Topical Gel
- **DRUG:** HT-001 Placebo

## Key facts

- **NCT ID:** NCT05639933
- **Lead sponsor:** Hoth Therapeutics, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-19
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05639933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05639933, "Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05639933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*